Financial Report: Sanofi 3Q11

Sanofi 3Q11

2Q Revenues: €8.8 billion (+5%)

2Q Earnings: €2.4 billion (-3%)

YTD Revenues: €24.9 billion (+1%)

YTD Earnings: €4.3 billion (-15%)

Comments: Pharmaceutical sales were €6.9 billion in the quarter (+10%). Lantus sales were up 14% to €968.0 million. Eloxatin sales were €310.0 million, up 179%. Taxotere sales were down 65% to €186.0 million and Lovenox sales were down 16% to €494.0 million, due to generic competition. Genzyme sales were €768.0 million, up 7% and accounted for 69% of total sales. Diabetes sales increased 12% driven by a strong performance in the U.S. and Emerging Markets, where Lantus sales growth was 15% and 23%, respectively. Vaccines grew 17% due to demand for seasonal flu vaccines in the U.S. Consumer Health Care sales were €665.0 million (+20%), driven by Allegra OTC launch in the U.S.  Unfavorable currency exchange impacted results by 5%.